Product Information
MESALAMINE DR 400 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $2.6990 per EA under NDC 00093590786. Its NADAC has been published 377 times since Jul 17, 2019.
FDA first approved this application on May 9, 2019.
Strength
400 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093590786
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA207873FDA Approved
5/9/2019
On Market Since
5/9/2019
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE DR 400 MG CAPSULE has been published 377 times since Jul 17, 2019, and over the history we have for it it has risen 5.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.6990 per EA |
|---|---|
| All-time high | $2.6990 (Sep 30, 2026) |
| All-time low | $1.5286 (Jul 17, 2024) |
| 52-week high | $2.6990 |
| 52-week low | $2.0896 |
| Median price | $2.1206 |
| Average price | $2.1196 |
| Largest weekly change | +29.8% (Aug 21, 2024) |
| Weeks tracked | 377 |
| Tracking since | Jul 17, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE DR 400 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE DR 400 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $2.6990 per EA (NDC 00093590786), effective Sep 30, 2026.
How has the price of MESALAMINE DR 400 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MESALAMINE DR 400 MG CAPSULE has risen 5.3%. It has been tracked across 377 weekly CMS publications since Jul 17, 2019.
What are the highest and lowest recorded NADAC prices for MESALAMINE DR 400 MG CAPSULE?
Since Jul 17, 2019, the NADAC for MESALAMINE DR 400 MG CAPSULE has ranged from a low of $1.5286 (Jul 17, 2024) to a high of $2.6990 (Sep 30, 2026), with a median of $2.1206 per EA.
Are there cheaper alternatives to MESALAMINE DR 400 MG CAPSULE?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MESALAMINE DR 400 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures MESALAMINE DR 400 MG CAPSULE?
MESALAMINE DR 400 MG CAPSULE (NDC 00093590786) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.